Literature DB >> 22747504

Utility of hepatocyte nuclear factor-1β as a diagnostic marker in ovarian carcinomas with clear cells.

Yu-Chien Kao1, Ming-Chieh Lin, Wei-Chou Lin, Yung-Ming Jeng, Tsui-Lien Mao.   

Abstract

AIMS: Overexpression of hepatocyte nuclear factor-1β (HNF-1β) has been found in ovarian clear cell carcinoma (OCCC) but not in other types of ovarian carcinoma. The aim of this study was to clarify whether the overexpression of HNF-1β is specific for OCCC, and does not occur in ovarian carcinoma with clear cell change. METHODS AND
RESULTS: Immunohistochemistry was performed on 178 ovarian carcinomas with clear cells (80 OCCCs, 60 high-grade serous, 25 endometrioid, and 13 mixed endometrioid and clear cell), 22 ovarian high-grade serous carcinomas without clear cells, 41 renal cell carcinomas (RCCs) and 20 hepatocellular carcinomas (HCCs) with clear cytoplasm. Results were evaluated using an H-score (percentage × intensity). Most OCCCs were diffusely and strongly positive (mean H-score 15.1). High-grade serous carcinoma and endometrioid carcinoma with clear cells were usually negative or focally and weakly positive (mean H-scores 1.5 and 1.7, respectively). High-grade serous carcinoma without clear cells had a mean H-score of 0.77. The mean H-scores of the endometrioid and clear cell components in mixed endometrioid and clear cell carcinoma were 6.2 and 15.7, respectively. HNF-1β was expressed in 95.1% of RCCs and in 30% of HCCs.
CONCLUSIONS: The diagnosis of ovarian carcinomas with clear cells can be made with greater accuracy by using the intensity and extent of immunoreactivity for HNF-1β.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22747504     DOI: 10.1111/j.1365-2559.2012.04267.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

1.  HNF-1β in ovarian carcinomas with serous and clear cell change.

Authors:  Deborah DeLair; Guangming Han; Julie A Irving; Samuel Leung; Carol A Ewanowich; Teri A Longacre; Cyril B Gilks; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2013-11       Impact factor: 2.762

2.  Diagnostic value of dual detection of hepatocyte nuclear factor 1 beta (HNF-1β) and napsin A for diagnosing ovarian clear cell carcinoma.

Authors:  Qing Li; Xin Zeng; Xue Cheng; Jingmin Zhang; Jie Ji; Jinsong Wang; Kemei Xiong; Qiong Qi; Wenbin Huang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 3.  A review on hepatocyte nuclear factor-1beta and tumor.

Authors:  Dan-Dan Yu; Shi-Wei Guo; Ying-Ying Jing; Yu-Long Dong; Li-Xin Wei
Journal:  Cell Biosci       Date:  2015-10-13       Impact factor: 7.133

4.  Next-Generation Sequencing Approach in Methylation Analysis of HNF1B and GATA4 Genes: Searching for Biomarkers in Ovarian Cancer.

Authors:  Ivana Bubancova; Helena Kovarikova; Jan Laco; Ema Ruszova; Ondrej Dvorak; Vladimir Palicka; Marcela Chmelarova
Journal:  Int J Mol Sci       Date:  2017-02-22       Impact factor: 5.923

Review 5.  Hepatocyte nuclear factor 1 beta: A perspective in cancer.

Authors:  Shubhra Chandra; Srilakshmi Srinivasan; Jyotsna Batra
Journal:  Cancer Med       Date:  2021-02-13       Impact factor: 4.452

6.  Endometrial Tumor Classification by Histomorphology and Biomarkers in the Nurses' Health Study.

Authors:  Jaclyn C Watkins; Michael J Downing; Marta Crous-Bou; Evan L Busch; Maxine Chen; Immaculata De Vivo; George L Mutter
Journal:  J Cancer Epidemiol       Date:  2021-03-12

Review 7.  Nicotinamide N-Methyltransferase: An Emerging Protagonist in Cancer Macro(r)evolution.

Authors:  Richard B Parsons; Paul D Facey
Journal:  Biomolecules       Date:  2021-09-28

8.  Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.

Authors:  Shuang Ye; Jiaxin Yang; Yan You; Dongyan Cao; Huifang Huang; Ming Wu; Jie Chen; Jinghe Lang; Keng Shen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.